Efficacy of immune rabbit sera in a mouse model of progressive vaccinia. Groups of 6-week old SCID/NCr mice (n = 7/group) were scarified with VACV, then treated i.p. with PBS (placebo), VIGIV (10 mg), QVPA (1:10; 1:100), or NRS (1:10) on days 2, 5, 10, and 15. (A) Survival was monitored out to 60 days postinfection. VIGIV and both QVPA dose groups showed a statistically significant increase (p < 0.05) in median survival time compared to placebo or NRS. (B) Primary lesion size on day 19 was determined from digital photographs and compared using one way ANOVA and Tukey's multiple comparison. Treatment with VIGIV or either dose of QVPA resulted in statistically significant reduction (p < 0.01) in lesion area.